Skip to main content
BioNxt Solutions Inc. logo

BioNxt Solutions Inc. — Investor Relations & Filings

Ticker · BNXT ISIN · CA0909741062 LEI · 254900VZ478Z39V2NM18 CSE Manufacturing
Open in API
Filings indexed 244 across all filing types
Latest filing 2026-01-23 Capital/Financing Update
Country CA Canada
Listing CSE BNXT

About BioNxt Solutions Inc.

https://bionxt.com/

BioNxt Solutions Inc. is a clinical-stage bioscience company focused on developing next-generation drug formulations and advanced delivery systems. The company specializes in high-performance solutions, including sublingual thin films and transdermal patches, designed to enhance bioavailability and patient compliance across critical therapeutic areas. BioNxt's R&D pipeline targets neurology, immunology, oncology, and mental health. Core platforms include advanced drug delivery systems for chronic diseases, a targeted chemotherapy platform designed to reduce systemic toxicity by delivering cytotoxic agents directly to tumors, and a proprietary library of engineered psychedelic compounds for neurological and psychiatric conditions. The company also develops diagnostic screening tests and active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Pricing Supplement' issued by CIBC, which details the terms, structure, and offering of 'Autocallable Notes'. This type of document is a standard financial instrument offering related to capital raising and debt financing. According to the provided definitions, documents detailing fundraising, financing activities, or capital structure changes fall under the 'CAP' (Capital/Financing Update) category. It is not an annual report, earnings release, or a simple announcement, but a formal offering document for structured notes.
2026-01-23 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing a debt-for-equity swap (debt settlement) where the company will issue new common shares to creditors. This falls under the category of capital structure changes and share issuance. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate classification for announcements regarding new share issues or capital changes.
2026-01-23 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing preclinical study results for a drug delivery technology. It does not pertain to financial reporting (not an annual, interim, or earnings release), corporate governance, board changes, dividends, or any other specific regulatory filing category. It is a general announcement that does not neatly fit into specialized categories, making “Regulatory Filings” (RNS) the appropriate fallback.
2026-01-21 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing a new letter agreement for the acquisition of intellectual property and a co-development partnership. This type of corporate activity, specifically involving strategic partnerships and intellectual property acquisition, falls under the category of M&A Activity (TAR) as it relates to business expansion and collaborative agreements.
2025-12-17 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release issued by BioNxt Solutions announcing the grant of a patent by the Eurasian Patent Organization. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and intellectual property, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2025-12-17 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by BioNxt Solutions Inc. regarding the advancement of a new drug formulation (cladribine ODF). It discusses product development, market opportunities, and company strategy. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication announcement. As it is a general corporate announcement regarding business operations and product development, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-12-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.